Cargando…

Retraction: Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507390/ https://www.ncbi.nlm.nih.gov/pubmed/37731508 http://dx.doi.org/10.3389/fimmu.2023.1285126

Ejemplares similares

Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges
por: Razeghian, Ehsan, et al.
Publicado: (2021)

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis
por: La Manna, Marco P., et al.
Publicado: (2020)

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
por: Bedard, Melissa, et al.
Publicado: (2017)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

HTNV Sensitizes Host Toward TRAIL-Mediated Apoptosis—A Pivotal Anti-hantaviral Role of TRAIL
por: Chen, Qing-Zhou, et al.
Publicado: (2020)

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy
por: Miao, Keyan, et al.
Publicado: (2023)

Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies
por: Lam, Pui Yeng, et al.
Publicado: (2017)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy
por: Sachamitr, Patty, et al.
Publicado: (2014)

Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy
por: Tullett, Kirsteen M., et al.
Publicado: (2014)

Harnessing NK Cells for Cancer Treatment
por: Minetto, Paola, et al.
Publicado: (2019)

Harnessing the Immunogenic Potential of Gold Nanoparticle-Based Platforms as a Therapeutic Strategy in Breast Cancer Immunotherapy: A Mini Review
por: Chen, Xiao-Yang, et al.
Publicado: (2022)

Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
por: Clappaert, Emile J., et al.
Publicado: (2018)

Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries
por: Montinaro, Antonella, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

T cell immunotherapy for cervical cancer: challenges and opportunities
por: Yu, Lingfeng, et al.
Publicado: (2023)

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
por: Chen, Siqi, et al.
Publicado: (2021)

Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy
por: de Looff, Margot, et al.
Publicado: (2019)

Harnessing tumor-associated macrophages as aids for cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2019)

Harnessing the Microbiome to Enhance Cancer Immunotherapy
por: Nelson, Michelle H., et al.
Publicado: (2015)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy
por: Duan, Li-Juan, et al.
Publicado: (2022)

Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers
por: Nazim, Uddin MD., et al.
Publicado: (2017)

N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis
por: Estornes, Yann, et al.
Publicado: (2018)

Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis
por: Carr, Ryan M, et al.
Publicado: (2016)

Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023)

Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
por: Vela, Maria, et al.
Publicado: (2015)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
por: Paiardini, Mirko, et al.
Publicado: (2020)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
por: Peyraud, Florent, et al.
Publicado: (2022)

Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy
por: de Alencar, Viviane Teixeira L., et al.
Publicado: (2022)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

Upregulated TRAIL and Reduced DcR2 Mediate Apoptosis of Decidual PMN-MDSC in Unexplained Recurrent Pregnancy Loss
por: Li, Congcong, et al.
Publicado: (2020)

Immunotherapy for Glioblastoma: Current Progress and Challenges
por: Yu, Miranda W., et al.
Publicado: (2021)

Harnessing the antitumor potential of macrophages for cancer immunotherapy
por: Long, Kristen B, et al.
Publicado: (2013)

Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
por: Yan, Liang, et al.
Publicado: (2021)

TRAIL-Induced Apoptosis in TRAIL-Resistant Breast Carcinoma Through Quercetin Cotreatment
por: Manouchehri, Jasmine M, et al.
Publicado: (2018)

Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
por: Zhang, Zengfu, et al.
Publicado: (2021)

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types
por: Tomasello, Elena, et al.
Publicado: (2014)

Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
por: Shah, Deep, et al.
Publicado: (2023)

The challenge of making the right choice: patient avatars in the era of cancer immunotherapies
por: Kayser, Charlotte, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ughmaq72ec86krnc9m7ak187ja